The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer.
Kim, S T; Do, I-G; Lee, J; Sohn, I; Kim, K-M; Kang, W K.
Clin Transl Oncol
; 17(6): 462-8, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25445175
The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer
Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
Prediktivní a prognostické faktory karcinomu zaludku.
Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
PCR-sequencing is a complementary method to amplification refractory mutation system for EGFR gene mutation analysis in FFPE samples.
Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.